Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

NCT07436663 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
DRUG: Sitagliptin (DPP4 inhibitor)
OTHER: Standard Care (in control arm)

Sponsor

Tanta University